drugset / Trial / NCT00638118

Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

NCT00638118

Phase 4 Completed 48 enrolled Sanofi
RandomizedCrossoverDouble-blindTreatment

Summary

Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals and flares induced by seasonal allergen.

Timeline

Start
2003-02
Primary completion
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown 180 mg

Indications